Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cultured autologous keratinocytes, developed by the Association of Dutch Burn Centres, is an advanced therapy medicinal product (ATMP) designed for the treatment of acute full-thickness burn wounds. The therapy consists of a co-culture of the patient's own keratinocytes and melanocytes, which are expanded in vitro without the use of mouse feeder layers to eliminate xenogenic risks. In clinical application, these cells are typically seeded onto a collagen/elastin carrier and applied to the wound bed in combination with a meshed split-skin autograft. This approach aims to accelerate re-epithelialization, reduce the time to wound closure, and improve the long-term functional and aesthetic quality of the resulting scar compared to standard autografting alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cultured autologous keratinocytes (Association of Dutch Burn Centres).